A Reversal for Aslan Pharmaceuticals Limited – American Depositar (NASDAQ:ASLN) Is Near. The Stock Has Decrease in Shorts

October 2, 2018 - By Adrian Mccoy

The stock of Aslan Pharmaceuticals Limited – American Depositar (NASDAQ:ASLN) registered a decrease of 90% in short interest. ASLN’s total short interest was 200 shares in October as published by FINRA. Its down 90% from 2,000 shares, reported previously.

The stock decreased 0.63% or $0.05 during the last trading session, reaching $7.95. About 1 shares traded. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) has 0.00% since October 2, 2017 and is . It has underperformed by 15.62% the S&P500.

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company has market cap of $215.52 million. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors. It currently has negative earnings. It is also developing ASLAN004, a monoclonal IL4/IL13 antibody that is under preclinical development for asthma and other tumor types; and ASLAN005, a monoclonal antibody, which is under preclinical development for RON, an immune checkpoint inhibitor.

More recent ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) news were published by: Nasdaq.com which released: “ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting” on September 21, 2018. Also Nasdaq.com published the news titled: “ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference” on September 04, 2018. Nasdaq.com‘s news article titled: “ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China” with publication date: September 17, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>